Johnson & Johnson (NYSE:JNJ) Shares Purchased by Cypress Wealth Services LLC

Cypress Wealth Services LLC lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,662 shares of the company’s stock after acquiring an additional 111 shares during the period. Cypress Wealth Services LLC’s holdings in Johnson & Johnson were worth $1,080,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the company. Atlas Private Wealth Advisors raised its position in shares of Johnson & Johnson by 3.2% in the third quarter. Atlas Private Wealth Advisors now owns 26,709 shares of the company’s stock valued at $4,329,000 after buying an additional 831 shares during the last quarter. BSN CAPITAL PARTNERS Ltd acquired a new position in Johnson & Johnson in the third quarter valued at $14,585,000. Wealth Group Ltd purchased a new position in Johnson & Johnson during the third quarter worth about $213,000. TL Private Wealth grew its holdings in Johnson & Johnson by 41.1% in the 3rd quarter. TL Private Wealth now owns 2,221 shares of the company’s stock valued at $354,000 after buying an additional 647 shares during the period. Finally, Somerset Trust Co lifted its holdings in shares of Johnson & Johnson by 1.3% during the 3rd quarter. Somerset Trust Co now owns 36,263 shares of the company’s stock worth $5,877,000 after acquiring an additional 478 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on JNJ shares. The Goldman Sachs Group dropped their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Morgan Stanley upped their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. Royal Bank of Canada boosted their target price on Johnson & Johnson from $175.00 to $178.00 and gave the stock an “outperform” rating in a report on Tuesday. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, September 30th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $173.43.

Johnson & Johnson Stock Up 0.4 %

NYSE JNJ traded up $0.69 during mid-day trading on Thursday, reaching $161.34. 396,395 shares of the company’s stock traded hands, compared to its average volume of 7,026,207. The company has a fifty day simple moving average of $162.65 and a 200-day simple moving average of $154.41. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a market cap of $388.29 billion, a price-to-earnings ratio of 10.02, a P/E/G ratio of 2.69 and a beta of 0.52. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.80 earnings per share. As a group, equities research analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.07%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.